Defensins drove psoriatic itch as well as psoriatic inflammation in mice

Design

preclinical - keratinocyte defensin cluster knockout mouse, imiquimod model, plus neuronal activation assays

Population

mice; human β-defensin 2 tested on small-diameter sensory neurons

Primary outcome

psoriasiform inflammation, immune cell infiltration and scratching behaviour

Effect

defensin deletion reduced hyperkeratosis, erythema, scaling, neutrophil and IL-17+ γδ T cell infiltration, and scratching; human β-defensin 2 activated Mrgpra3 neurons

β-defensins are markedly upregulated in psoriatic keratinocytes and have been regarded mainly as antimicrobial peptides. This study deleted the defensin gene cluster in keratinocytes in mice and applied imiquimod to induce psoriasiform disease.

The knockout mice had less hyperkeratosis, erythema and scaling, lower expression of inflammatory cytokines and chemokines, and reduced infiltration by neutrophils and IL-17+ γδ T cells - placing defensins upstream of the type 17 axis that current biologics target downstream. The behavioural result is the one that stands out: losing defensins reduced scratching, and human β-defensin 2 applied directly activated small-diameter Mrgpra3 sensory neurons, the pruriceptive population, producing robust scratching.

This is mouse work with a human peptide tested on neurons, and nothing about it is ready for a clinic. But it speaks to a real gap. Itch in psoriasis is common, under-recorded and often persists when plaques clear on a biologic, and it has been hard to explain through a purely immunological model. A keratinocyte peptide that both amplifies type 17 inflammation and directly fires an itch neuron is a mechanism that would account for both halves. The practical action today is simply to ask about itch and record it, because a target that treats it is being looked for.

• Ask about itch at every psoriasis review and score it - it is frequently omitted from the assessment entirely
• Do not assume a clear plaque means resolved itch; record the two separately
• Where itch persists on an effective biologic, treat it as a symptom needing its own management rather than as treatment failure
• Keep this in the research column when counselling - there is no defensin-directed therapy

Why it matters

It offers an explanation for the psoriatic itch that persists after the plaques respond.

Don't overread it

This is a knockout mouse model with imiquimod-induced disease - it identifies a target, not a treatment.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.